The drug screening market size has grown rapidly in recent years. It will grow from $9.72 billion in 2025 to $11.18 billion in 2026 at a compound annual growth rate (CAGR) of 15%. The growth in the historic period can be attributed to increasing workplace drug testing programs, expansion of clinical trial activities, rising law enforcement screening requirements, growth of diagnostic laboratories, wider availability of rapid test kits.
The drug screening market size is expected to see rapid growth in the next few years. It will grow to $19.2 billion in 2030 at a compound annual growth rate (CAGR) of 14.5%. The growth in the forecast period can be attributed to increasing adoption of ai-enabled screening analytics, rising demand for portable drug testing devices, expansion of regulatory drug compliance testing, growing use of real-time reporting systems, innovation in multi-panel drug screening. Major trends in the forecast period include increasing adoption of rapid drug testing kits, rising use of automated laboratory screening systems, growing integration of digital reporting solutions, expansion of point-of-care drug testing, enhanced focus on high-accuracy detection.
The growth of the drug screening market is expected to be driven by the increasing prevalence of drug and alcohol consumption. Drug addiction, a condition affecting both brain and behavior, leads to the inability to control the use of legal or illegal substances such as alcohol, marijuana, and nicotine. As drug and alcohol addiction rise, the associated health risks also increase, necessitating the demand for drug screening. IFor instance, in June 2025, According to the United Nations Office on Drugs and Crime, a Austria based United Nations office, reported 316 million people used a drug (excluding alcohol and tobacco) in 2023, or six per cent of the population aged between 15 and 64,. With 244 million users, cannabis remains the most widely used drug, followed by opioids (61 million), amphetamines (30.7 million), cocaine (25 million) and “ecstasy” (21 million). New groups of vulnerable people fleeing hardship, instability and conflict could cause these numbers to increase further, the report warns. The ongoing pandemic further exacerbated drug risks, with youth cannabis intake increasing up to four times in certain regions. The escalating drug and alcohol consumption significantly contribute to the growth of the drug screening market.
Companies operating in the drug screening market are increasingly emphasizing strategic partnerships and collaborations to strengthen financial capabilities, enhance product offerings, and expand geographic reach. A strategic collaboration involves an agreement between two or more independent organizations to jointly pursue defined objectives while maintaining operational autonomy. For example, in February 2025, Neopharma Technologies, a Canada-based drug testing company, and Impairment Science, a U.S.-based cognitive assessment company, announced a strategic partnership focused on advancing drug and impairment testing. The collaboration integrates Neopharma’s NEOVAULT platform, which digitally interprets and reports rapid drug test results, with Impairment Science’s DRUID cognitive impairment assessment, an AI-enabled tool designed to evaluate functional impairment. By combining these technologies, the partnership seeks to improve the precision and practical relevance of drug screening by delivering real-time insights into both substance detection and functional impairment. This initiative has the potential to enhance workplace safety, support regulatory compliance, and improve decision-making in safety-sensitive environments through the use of AI and digital reporting solutions.
In June 2024, Premier Biotech, a U.S.-based provider of urine and oral fluid drug testing solutions and toxicology services, acquired Desert Tox, LLC for an undisclosed amount. Through this acquisition, Premier Biotech seeks to expand its laboratory testing capabilities, reinforce its position in the oral-fluid drug testing market, and extend its national customer reach across workplace, government, and occupational health segments. Desert Tox, LLC is a U.S.-based company that delivers SAMHSA-certified urine and oral-fluid drug testing services to employment, government, and clinical clients.
Major companies operating in the drug screening market are Laboratory Corporation, Quest Diagnostics Incorporated, OraSure Technologies Inc., Alfa Scientific Designs Inc., Abbott Laboratories, Thermo Fisher Scientific Inc., Drägerwerk AG & Co. KGaA, LifeLoc Technologies Inc., MPD Inc., Omega Laboratories Inc., Premier Biotech Inc., Psychemedics Corporation, F. Hoffmann-La Roche Ltd., Shimadzu Corporation, Siemens Healthineers AG, Medtox Scientific Inc., American Screening Corporation, Clinical Reference Laboratory Inc., Express Diagnostics International Inc., Global Drug Testing Services, Kroll Laboratory Specialists Inc., Medscreen Laboratories, National Screening Centers Inc., American Bio Medica Corporation, Mayo Clinic Laboratories, ACM Global Laboratories, Intertek Group plc, Eurofins Scientific SE.
North America was the largest region in the drug screening market in 2025. Asia-Pacific is expected to be the fastest-growing region in the drug screening market during the forecast period. The regions covered in the drug screening market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the drug screening market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the drug screening market by increasing costs of imported reagents, assay kits, analytical instruments, sensors, and laboratory equipment. Diagnostic laboratories and law enforcement agencies in North America and Europe are most affected due to reliance on imported consumables, while Asia-Pacific faces cost pressure on test kit manufacturing. These tariffs are raising testing costs and procurement challenges. However, they are also encouraging domestic reagent production, localized kit assembly, and innovation in cost-efficient drug screening solutions.
The drug screening market research report is one of a series of new reports that provides drug screening market statistics, including drug screening industry global market size, regional shares, competitors with a drug screening market share, detailed drug screening market segments, market trends and opportunities, and any further data you may need to thrive in the drug screening industry. This drug screening market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Drug screening is an approach used for drug testing, specifically designed and optimized for clinical trials. It involves the analysis of blood, urine, hair, or saliva to detect the presence of chemicals, pollutants, and other illicit substances left in the body due to drug usage.
The main types of drug screening products include rapid testing devices, consumables, and other related items. Rapid testing devices are user-friendly screening tools that provide quicker results compared to traditional laboratory tests. Various samples, such as oral fluid, hair, urine, breath, and others, are used in drug screening. These screenings find applications in drug testing laboratories, workplaces, criminal justice and law enforcement, hospitals, drug treatment centers, individual users, pain management centers, schools, and colleges.
The drug screening market consists of sales of testing kits, reagents, and other supplies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The drug screening market size is expected to see rapid growth in the next few years. It will grow to $19.2 billion in 2030 at a compound annual growth rate (CAGR) of 14.5%. The growth in the forecast period can be attributed to increasing adoption of ai-enabled screening analytics, rising demand for portable drug testing devices, expansion of regulatory drug compliance testing, growing use of real-time reporting systems, innovation in multi-panel drug screening. Major trends in the forecast period include increasing adoption of rapid drug testing kits, rising use of automated laboratory screening systems, growing integration of digital reporting solutions, expansion of point-of-care drug testing, enhanced focus on high-accuracy detection.
The growth of the drug screening market is expected to be driven by the increasing prevalence of drug and alcohol consumption. Drug addiction, a condition affecting both brain and behavior, leads to the inability to control the use of legal or illegal substances such as alcohol, marijuana, and nicotine. As drug and alcohol addiction rise, the associated health risks also increase, necessitating the demand for drug screening. IFor instance, in June 2025, According to the United Nations Office on Drugs and Crime, a Austria based United Nations office, reported 316 million people used a drug (excluding alcohol and tobacco) in 2023, or six per cent of the population aged between 15 and 64,. With 244 million users, cannabis remains the most widely used drug, followed by opioids (61 million), amphetamines (30.7 million), cocaine (25 million) and “ecstasy” (21 million). New groups of vulnerable people fleeing hardship, instability and conflict could cause these numbers to increase further, the report warns. The ongoing pandemic further exacerbated drug risks, with youth cannabis intake increasing up to four times in certain regions. The escalating drug and alcohol consumption significantly contribute to the growth of the drug screening market.
Companies operating in the drug screening market are increasingly emphasizing strategic partnerships and collaborations to strengthen financial capabilities, enhance product offerings, and expand geographic reach. A strategic collaboration involves an agreement between two or more independent organizations to jointly pursue defined objectives while maintaining operational autonomy. For example, in February 2025, Neopharma Technologies, a Canada-based drug testing company, and Impairment Science, a U.S.-based cognitive assessment company, announced a strategic partnership focused on advancing drug and impairment testing. The collaboration integrates Neopharma’s NEOVAULT platform, which digitally interprets and reports rapid drug test results, with Impairment Science’s DRUID cognitive impairment assessment, an AI-enabled tool designed to evaluate functional impairment. By combining these technologies, the partnership seeks to improve the precision and practical relevance of drug screening by delivering real-time insights into both substance detection and functional impairment. This initiative has the potential to enhance workplace safety, support regulatory compliance, and improve decision-making in safety-sensitive environments through the use of AI and digital reporting solutions.
In June 2024, Premier Biotech, a U.S.-based provider of urine and oral fluid drug testing solutions and toxicology services, acquired Desert Tox, LLC for an undisclosed amount. Through this acquisition, Premier Biotech seeks to expand its laboratory testing capabilities, reinforce its position in the oral-fluid drug testing market, and extend its national customer reach across workplace, government, and occupational health segments. Desert Tox, LLC is a U.S.-based company that delivers SAMHSA-certified urine and oral-fluid drug testing services to employment, government, and clinical clients.
Major companies operating in the drug screening market are Laboratory Corporation, Quest Diagnostics Incorporated, OraSure Technologies Inc., Alfa Scientific Designs Inc., Abbott Laboratories, Thermo Fisher Scientific Inc., Drägerwerk AG & Co. KGaA, LifeLoc Technologies Inc., MPD Inc., Omega Laboratories Inc., Premier Biotech Inc., Psychemedics Corporation, F. Hoffmann-La Roche Ltd., Shimadzu Corporation, Siemens Healthineers AG, Medtox Scientific Inc., American Screening Corporation, Clinical Reference Laboratory Inc., Express Diagnostics International Inc., Global Drug Testing Services, Kroll Laboratory Specialists Inc., Medscreen Laboratories, National Screening Centers Inc., American Bio Medica Corporation, Mayo Clinic Laboratories, ACM Global Laboratories, Intertek Group plc, Eurofins Scientific SE.
North America was the largest region in the drug screening market in 2025. Asia-Pacific is expected to be the fastest-growing region in the drug screening market during the forecast period. The regions covered in the drug screening market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the drug screening market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the drug screening market by increasing costs of imported reagents, assay kits, analytical instruments, sensors, and laboratory equipment. Diagnostic laboratories and law enforcement agencies in North America and Europe are most affected due to reliance on imported consumables, while Asia-Pacific faces cost pressure on test kit manufacturing. These tariffs are raising testing costs and procurement challenges. However, they are also encouraging domestic reagent production, localized kit assembly, and innovation in cost-efficient drug screening solutions.
The drug screening market research report is one of a series of new reports that provides drug screening market statistics, including drug screening industry global market size, regional shares, competitors with a drug screening market share, detailed drug screening market segments, market trends and opportunities, and any further data you may need to thrive in the drug screening industry. This drug screening market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Drug screening is an approach used for drug testing, specifically designed and optimized for clinical trials. It involves the analysis of blood, urine, hair, or saliva to detect the presence of chemicals, pollutants, and other illicit substances left in the body due to drug usage.
The main types of drug screening products include rapid testing devices, consumables, and other related items. Rapid testing devices are user-friendly screening tools that provide quicker results compared to traditional laboratory tests. Various samples, such as oral fluid, hair, urine, breath, and others, are used in drug screening. These screenings find applications in drug testing laboratories, workplaces, criminal justice and law enforcement, hospitals, drug treatment centers, individual users, pain management centers, schools, and colleges.
The drug screening market consists of sales of testing kits, reagents, and other supplies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Drug Screening Market Characteristics
3. Drug Screening Market Supply Chain Analysis
4. Global Drug Screening Market Trends and Strategies
5. Drug Screening Market Analysis of End Use Industries
7. Global Drug Screening Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Drug Screening Total Addressable Market (TAM) Analysis for the Market
9. Drug Screening Market Segmentation
10. Drug Screening Market Regional and Country Analysis
11. Asia-Pacific Drug Screening Market
12. China Drug Screening Market
13. India Drug Screening Market
14. Japan Drug Screening Market
15. Australia Drug Screening Market
16. Indonesia Drug Screening Market
17. South Korea Drug Screening Market
18. Taiwan Drug Screening Market
19. South East Asia Drug Screening Market
20. Western Europe Drug Screening Market
21. UK Drug Screening Market
22. Germany Drug Screening Market
23. France Drug Screening Market
24. Italy Drug Screening Market
25. Spain Drug Screening Market
26. Eastern Europe Drug Screening Market
27. Russia Drug Screening Market
28. North America Drug Screening Market
29. USA Drug Screening Market
30. Canada Drug Screening Market
31. South America Drug Screening Market
32. Brazil Drug Screening Market
33. Middle East Drug Screening Market
34. Africa Drug Screening Market
36. Drug Screening Market Competitive Landscape and Company Profiles
37. Drug Screening Market Other Major and Innovative Companies
40. Drug Screening Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Drug Screening Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses drug screening market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for drug screening? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The drug screening market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Products: Rapid Testing Devices; Consumables; Other Products2) By Sample Type: Oral Fluid Sample; Hair Sample; Urine Sample; Breath Sample; Other Sample Types
3) By End User: Drug Testing Laboratories; Workplaces; Criminal Justice and Law Enforcement Agencies; Hospitals; Drug Treatment Centers; Individual Users; Pain Management Centers; Schools and Colleges
Subsegments:
1) By Rapid Testing Devices: Urine Drug Test Kits; Saliva Drug Test Kits; Blood Drug Test Devices; Instant Test Strips2) By Consumables: Reagents and Assays; Sample Collection Devices; Calibration Standards
3) By Other Products: Laboratory Equipment; Software Solutions; Storage and Transport Solutions
Companies Mentioned: Laboratory Corporation; Quest Diagnostics Incorporated; OraSure Technologies Inc.; Alfa Scientific Designs Inc.; Abbott Laboratories; Thermo Fisher Scientific Inc.; Drägerwerk AG & Co. KGaA; LifeLoc Technologies Inc.; MPD Inc.; Omega Laboratories Inc.; Premier Biotech Inc.; Psychemedics Corporation; F. Hoffmann-La Roche Ltd.; Shimadzu Corporation; Siemens Healthineers AG; Medtox Scientific Inc.; American Screening Corporation; Clinical Reference Laboratory Inc.; Express Diagnostics International Inc.; Global Drug Testing Services; Kroll Laboratory Specialists Inc.; Medscreen Laboratories; National Screening Centers Inc.; American Bio Medica Corporation; Mayo Clinic Laboratories; ACM Global Laboratories; Intertek Group plc; Eurofins Scientific SE
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Drug Screening market report include:- Laboratory Corporation
- Quest Diagnostics Incorporated
- OraSure Technologies Inc.
- Alfa Scientific Designs Inc.
- Abbott Laboratories
- Thermo Fisher Scientific Inc.
- Drägerwerk AG & Co. KGaA
- LifeLoc Technologies Inc.
- MPD Inc.
- Omega Laboratories Inc.
- Premier Biotech Inc.
- Psychemedics Corporation
- F. Hoffmann-La Roche Ltd.
- Shimadzu Corporation
- Siemens Healthineers AG
- Medtox Scientific Inc.
- American Screening Corporation
- Clinical Reference Laboratory Inc.
- Express Diagnostics International Inc.
- Global Drug Testing Services
- Kroll Laboratory Specialists Inc.
- Medscreen Laboratories
- National Screening Centers Inc.
- American Bio Medica Corporation
- Mayo Clinic Laboratories
- ACM Global Laboratories
- Intertek Group plc
- Eurofins Scientific SE
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 11.18 Billion |
| Forecasted Market Value ( USD | $ 19.2 Billion |
| Compound Annual Growth Rate | 14.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 29 |
